Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers Academic Article uri icon

Overview

MeSH Major

  • Long-Term Care
  • Lung Neoplasms
  • Models, Theoretical

abstract

  • This is the first clinical implementation of an anti-cancer TKI regimen combining pulse and daily low-dose administration. This evolutionary modeling-based dosing schedule was well-tolerated but did not improve progression-free survival or prevent emergence of EGFR T790M, likely due to insufficient peak serum concentrations of erlotinib. This dosing schedule prevented progression of untreated or any new central nervous system metastases in all patients.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdw556

PubMed ID

  • 28073786

Additional Document Info

start page

  • 278

end page

  • 284

volume

  • 28

number

  • 2